TBPH
Theravance·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Strong Buy"
MACD Death Cross
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TBPH
Theravance Biopharma, Inc.
A biopharmaceutical company that developing small molecule medicines in the areas of infections, CNS/pain, respiratory disease
C/O Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080
--
Theravance Biopharma, Inc., was registered as a Cayman Islands exempted company limited by shares in July 2013. The company is a biopharmaceutical company focused on drug discovery, development and commercialization. The company's core purpose is to create drugs that can change people's lives. The company used decades of expertise to develop the FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Earnings Call
Q2/2025
Estimate EPS-0.12
Actual EPS-0.08
Estimate Revenue26.03M
Actual Revenue26.20M
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics
Aug 12,2025 06:59
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TBPH has released its 2025 Q3 earnings. EPS was reported at 0.07, versus the expected -0.05, beating expectations. The chart below visualizes how TBPH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TBPH has released its 2025 Q3 earnings report, with revenue of 19.99M, reflecting a YoY change of 18.51%, and net profit of 3.62M, showing a YoY change of 128.47%. The Sankey diagram below clearly presents TBPH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
